ERBB2 and breast cancer: Among women with DCIS/LCIS or M0 BC and detectable CTCs, 5 of 5 women with HER2-positive tumors versus 5 out of 12 women with HER2-negative primary tumors had ≥1 HER2-positive CTC (p = 0.03).